updated Wed. March 30, 2022
-
Dispatch Tribunal
March 11, 2018
Landscape Capital Management L.L.C. boosted its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 27.5% during the 4th quarter, according to the ... and six have assigned a buy rating to the company. Galapagos currently has a consensus rating of “Hold” and an average target price of $111.00.
StockNewsTimes
March 1, 2018
Finally, Zacks Investment Research upgraded Galapagos from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. GalapagosÃÂ ...
StockNewsTimes
March 1, 2018
Finally, BidaskClub downgraded Galapagos from a sell rating to a strong sell rating in a research report on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. Galapagos has an averageÃÂ ...
BangaloreWeekly
February 28, 2018
Finally, ValuEngine downgraded Galapagos from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Galapagos presently has aÃÂ ...
Week Herald
February 27, 2018
Galapagos NV logo ValuEngine upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a report issued on Friday, February ... a hold rating and seven have assigned a buy rating to the company. Galapagos has an average rating of Buy and an average target price of $111.00.
Week Herald
February 26, 2018
... Stifel Nicolaus reaffirmed a buy rating and set a $120.00 price target on shares of Galapagos in a research report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. GalapagosÃÂ ...
Dispatch Tribunal
February 20, 2018
Finally, ValuEngine cut Galapagos from a hold rating to a sell rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has a consensus rating of Buy andÃÂ ...
StockNewsTimes
February 18, 2018
Finally, BidaskClub cut Galapagos from a sell rating to a strong sell rating in a research note on Saturday, December 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Galapagos has an averageÃÂ ...
Seeking Alpha
December 19, 2017
Gilead made a $425 million investment in Galapagos shares, which bought them 6,760,701 shares of Galapagos, 13.27% of the total number of outstanding shares. In addition to that, Gilead paid a $300M license payment and further payments up to $1.35B can come from royalties and profit sharing.
Healio
December 19, 2017
Biotech company Galapagos has opted to co-promote filgotinib with its partner Gilead Sciences should the drug be approved in Europe, according to a press release. Filgotinib is an investigational oral Janus kinase 1 (JAK1)-selective inhibitor under evaluation in Crohn's disease, ulcerative colitis andÃÂ ...
Seeking Alpha
November 8, 2017
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene's dramatic failure in Crohn's Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody's CD pipeline. The Celgene (NASDAQ:CELG) drug was thought toÃÂ ...
Nasdaq
October 26, 2017
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues ofÃÂ ...
Investopedia
September 28, 2016
The stock price of NASDAQ-listed Belgian company Galapagos NV ADR (GLPG) started soaring mid-September onwards amid rumors of the company being a possible takeover target by Gilead Sciences Inc. (GILD). Following a 10-day long rally which resulted in a 35% spike in share price, the price isÃÂ ...
registrarjournal.com
December 31, 1999
Finally, Zacks Investment Research downgraded Galapagos from a hold rating to a sell rating in a research report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Galapagos currently has anÃÂ ...
Dispatch Tribunal
December 31, 1999
... target on shares of Galapagos in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has an average rating of Buy and an average price target of $111.00.
BangaloreWeekly
February 25, 2018
Finally, ValuEngine lowered Galapagos from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. Galapagos presently has a consensusÃÂ ...
Dispatch Tribunal
February 23, 2018
... target on shares of Galapagos in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has an average rating of Buy and an average price target of $111.00.
StockNewsTimes
February 13, 2018
Galapagos NV logo ValuEngine upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a report published on Friday, ... given a hold rating and seven have assigned a buy rating to the company. Galapagos has an average rating of Buy and a consensus target price of $111.00.
TrueBlueTribune
February 7, 2018
... on shares of Galapagos in a research note on Sunday, October 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Galapagos currently has an average rating of “Buy” and an average price target of $111.00.
Dispatch Tribunal
February 5, 2018
... $92.00) on shares of Galapagos in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Galapagos currently has a consensus rating of Buy and an average target price of $111.00.
Dispatch Tribunal
January 18, 2018
Finally, ValuEngine lowered shares of Galapagos from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Galapagos presently has a consensus rating ofÃÂ ...
Dispatch Tribunal
January 2, 2018
Finally, ValuEngine downgraded Galapagos from a hold rating to a sell rating in a report on Friday, December 1st. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Galapagos currently has an average rating ofÃÂ ...
Dispatch Tribunal
December 20, 2017
Finally, Nomura boosted their price target on Galapagos from $108.00 to $124.00 and gave the company a “buy” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. GalapagosÃÂ ...
Healio
December 19, 2017
Biotech company Galapagos has opted to co-promote filgotinib with its partner Gilead Sciences should the drug be approved in Europe, according to a press release. Filgotinib is an investigational oral Janus kinase 1 (JAK1)-selective inhibitor under evaluation in Crohn's disease, ulcerative colitis andÃÂ ...
The Lincolnian Online
December 17, 2017
Galapagos (NASDAQ:GLPG) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on ... hold rating and six have given a buy rating to the company. Galapagos currently has an average rating of “Hold” and a consensus price target of $111.00.
Week Herald
December 16, 2017
... shares of Galapagos in a report on Thursday, September 14th. They set a “sector perform” rating and a $98.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. Galapagos hasÃÂ ...
Seeking Alpha
December 12, 2017
As with most recent Gilead articles, the one from Meyers also discusses the reason why GILD shares continue to underperform. Since mid-2015, Gilead has struggled due to a range of factors. The stock was initially impacted by the general sell-off in the biotech industry. The first of these happened in theÃÂ ...
Seeking Alpha
November 8, 2017
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene's dramatic failure in Crohn's Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody's CD pipeline. The Celgene (NASDAQ:CELG) drug was thought toÃÂ ...
Nasdaq
October 26, 2017
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues ofÃÂ ...
Nasdaq
October 26, 2017
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues ofÃÂ ...
The Pharma Letter
August 14, 2017
Belgian clinical-stage biotech company Galapagos (Euronext: GLPG) is currently working on an agent called GLPG1690, an inhibitor of autotaxin for use in patients with a lung disorder named idiopathic pulmonary fibrosis. This continues to be an area of unmet need, as only two drugs are currentlyÃÂ ...
Cystic Fibrosis News Today
March 1, 2017
Researchers conducting a Phase 1 study for cystic fibrosis (CF) have dosed their first healthy volunteer with a combination of the novel drugs GLPG2222 (a corrector) and GLPG2451 (a potentiator), the Belgian company Galapagos announced. The randomized, placebo-controlled study (NCT02788721)ÃÂ ...
BangaloreWeekly
December 31, 1999
One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. Galapagos currently has a consensus rating of “Buy” and a consensus target price of $111.00. Shares of Galapagos (GLPG) traded up $1.51 duringÃÂ ...
Dispatch Tribunal
December 31, 1999
Finally, ValuEngine cut Galapagos from a hold rating to a sell rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has a consensus rating of Buy andÃÂ ...
StockNewsTimes
December 31, 1999
Finally, BidaskClub cut Galapagos from a sell rating to a strong sell rating in a research note on Saturday, December 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Galapagos has an averageÃÂ ...
Dispatch Tribunal
December 31, 1999
Galapagos NV (NASDAQ:GLPG) – Stock analysts at Jefferies Group cut their FY2017 EPS estimates for shares of Galapagos in a report released on ... and seven have assigned a buy rating to the company. Galapagos presently has an average rating of “Hold” and a consensus target price of $111.00.
StockNewsTimes
December 31, 1999
Finally, ValuEngine lowered shares of Galapagos from a hold rating to a sell rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Galapagos currently has aÃÂ ...
The Lincolnian Online
December 2, 2017
... on shares of Galapagos in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. Galapagos presently has an average rating of “Hold” and a consensus price target of $111.00.
BangaloreWeekly
November 30, 2017
Finally, Nomura began coverage on shares of Galapagos NV in a report on Wednesday, March 1st. They issued a buy rating for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Galapagos NV has an average ...
The Ledger Gazette
November 30, 2017
Finally, BidaskClub upgraded Galapagos from a sell rating to a hold rating in a research note on Thursday, August 17th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Galapagos currently has a consensus rating of Buy and an average price ...
Seeking Alpha
November 8, 2017
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene's dramatic failure in Crohn's Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody's CD pipeline. The Celgene (NASDAQ:CELG) drug was thought to ...
The Ledger Gazette
October 29, 2017
Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Galapagos NV presently has an average rating of “Buy” and an average price target of $108.14. Galapagos NV (GLPG) traded up 1.20% during midday trading on Friday, reaching $97.17.
Nasdaq
October 26, 2017
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues of ...
The Pharma Letter
August 14, 2017
Belgian clinical-stage biotech company Galapagos (Euronext: GLPG) is currently working on an agent called GLPG1690, an inhibitor of autotaxin for use in patients with a lung disorder named idiopathic pulmonary fibrosis. This continues to be an area of unmet need, as only two drugs are currently ...
Cystic Fibrosis News Today
March 1, 2017
Researchers conducting a Phase 1 study for cystic fibrosis (CF) have dosed their first healthy volunteer with a combination of the novel drugs GLPG2222 (a corrector) and GLPG2451 (a potentiator), the Belgian company Galapagos announced. The randomized, placebo-controlled study (NCT02788721)Â ...
Investopedia
September 28, 2016
The stock price of NASDAQ-listed Belgian company Galapagos NV ADR (GLPG) started soaring mid-September onwards amid rumors of the company being a possible takeover target by Gilead Sciences Inc. (GILD). Following a 10-day long rally which resulted in a 35% spike in share price, the price is ...
Week Herald
August 15, 2017
Stifel Nicolaus increased their target price on shares of Galapagos NV ... a buy rating to the company. Galapagos NV presently has an averageÃÂ ...
The Cerbat Gem
August 14, 2017
Galapagos NV (NASDAQ:GLPG) was upgraded by stock analysts at ... a buy rating to the company. Galapagos NV presently has an averageÃÂ ...
The Pharma Letter (registration)
August 14, 2017
Belgian clinical-stage biotech company Galapagos (Euronext: GLPG) is currently working on an agent called GLPG1690, an inhibitor ofÃÂ ...
Week Herald
August 6, 2017
BidaskClub cut shares of Galapagos NV (NASDAQ:GLPG) from a hold ... rating to the company. Galapagos NV has an average rating of BuyÃÂ ...
